Principal Financial Group Inc Tyme Technologies, Inc. Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

Shares

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 10, 2022	SELL	$0.23 - $0.35 $4,488 - $6,829	-19,514 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$0.28 - $0.68 $307 - $746	-1,098 Reduced 5.33%	19,514 $7,000
Q4 2021 Feb 09, 2022	SELL	$0.6 - $1.04 $7,947 - $13,775	-13,246 Reduced 39.12%	20,612 $12,000
Q3 2021 Nov 09, 2021	SELL	$0.99 - $1.38 $5,431 - $7,570	-5,486 Reduced 13.94%	33,858 $35,000
Q2 2021 Aug 10, 2021	BUY	$1.14 - $1.87 $28,197 - $46,254	24,735 Added 169.31%	39,344 $49,000
Q1 2021 May 10, 2021	SELL	$1.34 - $3.53 $3,084 - $8,126	-2,302 Reduced 13.61%	14,609 $26,000
Q4 2020 Feb 08, 2021	BUY	$0.87 - $1.26 $5,293 - $7,667	6,085 Added 56.21%	16,911 $21,000
Q2 2020 Aug 05, 2020	BUY	$0.97 - $1.7 $10,501 - $18,404	10,826 New	10,826 $14,000
Q4 2019 Feb 05, 2020	SELL	$1.0 - $1.49 $10,815 - $16,114	-10,815 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$0.97 - $1.77 $10,490 - $19,142	10,815 New	10,815 $13,000
Q2 2019 Aug 12, 2019	SELL	$0.96 - $1.89 $12,376 - $24,365	-12,892 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$1.76 - $3.73 $22,689 - $48,087	12,892 New	12,892 $23,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.